• 1
    Tomizuka T, Takayama Y, Shobayashi T, Fukushima Y, Suzuki Y. Underlying medical conditions and hospitalization for pandemic (H1N1) 2009, Japan . Emerg Infect Dis2010; 16:16461647.
  • 2
    Helferty M, Vachon J, Tarasuk J, Rodin R, Spika J, Pelletier L. Incidence of hospital admissions and severe outcomes during the first and second waves of pandemic (H1N1) 2009. CMAJ2010; 182:19811987.
  • 3
    Duchini A, Viernes ME, Nyberg LM, Hendry M, Pockros PJ. Hepatic decompensation in patients with cirrhosis during infection with influenza A. Arch Intern Med2000; 160:113115.
  • 4
    Recommendations of the Advisory Committee on Immunization Practices (ACIP). Prevention and control of seasonal influenza with vaccines. MMWR2010; 60:RR-8, PP4.
  • 5
    Gaeta GB, Pariani E, Amendola A et al. Influenza vaccination in patients with cirrhosis and in liver transplant recipients. Vaccine2009; 27:33733375.
  • 6
    Gaeta GB, Stornaiuolo G, Precone DF, Amendola A, Zanetti AR. Immunogenicity and safety of an adjuvanted influenza vaccine in patients with decompensated cirrhosis. Vaccine2002; 20:B33B35.
  • 7
    Soesman NMR, Rimmelzwaan GF, Nieuwkoop NL et al. Efficacy of influenza vaccination in adult liver transplant recipients. J Med Virol2000; 61:8593.
  • 8
    Marinho RT, Pinto R, Santos ML, Lobos IV, Moura MC. Effects of interferon and ribavirin combination therapy on CD4+ proliferation, lymphocyte activation, and Th1 and Th2 cytokine profiles in chronic hepatitis C. J Viral Hepat2004; 11:206216.
  • 9
    Zhang YH, Isobe K, Iwamoto T, Nakashima I. Bidirectional control by glycyrrhizin of the growth response of lymphocytes stimulated through a receptor-by passed pathway. Immunol Lett1992; 32:147152.
  • 10
    Pugh RNH, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg1973; 60:646649.
  • 11
    WHO Global Influenza Surveillance Network. Identification of the haemagglutinin subtype of viral isolates by haemagglutination inhibition testing; in World Health Organization (eds): Manual for the Laboratory Diagnosis and Virological Surveillance of Influenza. Geneva: World Health Organization, 2011, pp. 4362.
  • 12
    European Committee for Proprietary Medical Products. Note for Guidance on Harmonisation of Requirements for Influenza Vaccines (CPMP/BWP/214/96). London: European Agency for the Evaluation of Medical Products, 1997.
  • 13
    Center for Biologics Evaluation and Research. Guidance for Industry: Clinical Data Needed to Support the Licensure of Pandemic Influenza Vaccines. Bethesda, MD: Food and Drug Administration, 2007.
  • 14
    Liang XF, Wang HQ, Wang JZ et al. Safety and immunogenicity of 2009 pandemic influenza A H1N1 vaccines in China: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet2010; 375:5666.
  • 15
    Greenberg ME, Lai MH, Hartel GF et al. Response to a monovalent 2009 influenza A (H1N1) vaccine. N Engl J Med2009; 361:24052413.
  • 16
    Zhu FC, Wang H, Fang HH et al. A novel influenza A (H1N1) vaccine in various age groups. N Engl J Med2009; 361:24142423.
  • 17
    Cook IF, Barr I, Hartel G, Pond D, Hampson AW. Reactogenicity and immunogenicity of an inactivated influenza vaccine administered by intramuscular or subcutaneous injection in elderly adults. Vaccine2006; 24:23952402.
  • 18
    Hara M, Hanaoka T, Mizushima T et al. Diminished immunogenicity to pandemic H1N1 2009 influenza vaccine in subjecte with severe motor and intellectual disability. Vaccine2011; 29:83238329.
  • 19
    Goodwin K, Viboud C, Simonsen L. Antibody response to influenza vaccination in the elderly: a quantitative review. Vaccine2006; 24:11591169.
  • 20
    Deng Y, Jing Y, Campbell AE, Gravenstein S. Age-related impaired type 1 T cell responses to influenza: reduced activation ex vivo, decreased expansion in CTL culture in vitro and blunted response to influenza vaccination in vivo in the elderly. J Immunol2004; 172:34373446.
  • 21
    Kang I, Hong MS, Nolasco H et al. Age-associated change in the frequency of memory CD4+ T cells impairs long term CD4+ T cell responses to influenza vaccine. J Immunol2004; 173:673681.
  • 22
    Saurwein-Teissl M, Lung TL, Marx F et al. Lack of antibody production following immunization in old age: association with CD8+ CD28- T cell clonal expansions and an imbalance in the production of Th1 and Th2 cytokines. J Immunol2002; 168:58935899.
  • 23
    Bellei NCJ, Carraro E, Castelo A, Granato CFH. Risk factors for poor immune response to influenza vaccination in elderly people. BJID2006; 10:269273.
  • 24
    Hara M, Tanaka K, Hirota Y. Immune response to influenza vaccine in healthy adults and the elderly: association with nutritional status. Vaccine2005; 23:14571463.
  • 25
    Vajo Z, Tamas F, Sinka L, Jankovics I. Safety and immunogenicity of 2009 pandemic influenza A H1N1 vaccines when administered alone or simultaneously with the seasonal influenza vaccine for the 2009-10 influenza season: a multicentre, randomised controlled trial. Lancet2010; 375:4955.
  • 26
    Ohfuji S, Fukushima W, Deguchi M et al. Immunogenicity of a monovalent 2009 influenza A (H1N1) vaccine among pregnant women: lowered antibody response by prior seasonal vaccination. J Infect Dis2011; 203:13011308.
  • 27
    Nolan T, McVernon J, Skeljo M et al. Immunogenicity of a monovalent 2009 influenza A (H1N1) vaccine in infants and children. JAMA2010; 303:3746.
  • 28
    Hobson D, Baker FA, Curry RL. Effects of influenza vaccines in stimulating antibody in volunteers with prior immunity. Lancet1973; 2:155156.
  • 29
    Hirota Y, Kaji M, Ide S, Goto S, Oka T. The hemagglutination inhibition antibody responses to an inactivated influenza vaccine among healthy adults: with special reference to the prevaccination antibody and its interaction with age. Vaccine1996; 14:15971602.
  • 30
    Kobayashi M, Ohfuji S, Fukushima W et al. Immunogenicity and reactogenicity of a monovalent inactivated 2009 influenza A (H1N1) vaccine in adolescents: with special reference to pre-existing titer. J Pediatr2012; 160: 632637.
  • 31
    Michaelis M, Geiler J, Naczk P et al. Glycyrrhizin exerts antioxidative effects in H5N1 influenza A virus-infected cells and inhibits virus replication and pro-inflammatory gene expression. PLoS One2011; 6:e19705.
  • 32
    Wolkerstorfer A, Kurz H, Bachhofner N, Szolar OH. Glycyrrhizin inhibits influenza A virus uptake into the cell. Antiviral Res2009; 83:171178.
  • 33
    Nakamura K, Hoshino Y, Kodama K, Yamamoto M. Reliability of self-reported body height and weight of adult Japanese women. J Biosoc Sci1999; 31:555558.
  • 34
    Hancock K, Veguilla V, Lu X et al. Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. N Engl J Med2009; 261:19451952.